About Nicox
Nicox is a company based in Valbonne (France) founded in 1996. Nicox has raised $271.01 million across 12 funding rounds from investors including Merck, Pfizer and HBM Healthcare Investments. The company has 5 employees as of December 31, 2024. Nicox has completed 2 acquisitions, including Aciex Therapeutics and Carragelose. Nicox offers products and services including NCX 470. Nicox operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Gyroscope and MeiraGTx, among others.
- Headquarter Valbonne, France
- Employees 5 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nicox Sa
-
Annual Revenue
$8.17 M (USD)13.84as on Dec 31, 2024
-
Net Profit
-$23.26 M (USD)-7.23as on Dec 31, 2024
-
EBITDA
-$38.39 M (USD)-81.87as on Dec 31, 2024
-
Total Equity Funding
$271.01 M (USD)
in 12 rounds
-
Latest Funding Round
$10.26 M (USD), Series C
Nov 22, 2022
-
Investors
Merck
& 6 more
-
Employee Count
5
as on Dec 31, 2024
-
Investments & Acquisitions
Aciex Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nicox
Nicox is a publicly listed company on the EURONEXT with ticker symbol ALCOX in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nicox
Nicox offers a comprehensive portfolio of products and services, including NCX 470.
Lead candidate for glaucoma treatment through nitric oxide mechanisms.
People of Nicox
Unlock access to complete
Funding Insights of Nicox
Nicox has successfully raised a total of $271.01M across 12 strategic funding rounds. The most recent funding activity was a Series C round of $10.26 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nicox
Nicox has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Pfizer and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Late-stage life sciences investments are managed via VC and PE.
|
Locked | Locked | Locked | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Nicox
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nicox
Nicox has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aciex Therapeutics and Carragelose.
Investment portfolio details for Nicox
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for ophthalmic allergy and inflammation were developed.
|
Locked | Locked | 2007 | Locked | |
|
Developer of therapeutic solutions for treating respiratory and infectious diseases
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Nicox
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Nicox
Detailed financials for Nicox
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nicox Comparisons
Peer comparison for Nicox
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nicox
Nicox operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Gyroscope and MeiraGTx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
Detailed competitors of Nicox
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nicox
Complete news archive for Nicox
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nicox
Nicox was founded in 1996 and raised its 1st funding round 8 years after it was founded.
Nicox is headquartered in Valbonne, France. It is registered at Valbonne, Provence-alpes-cote D'azur, France.
Andreas Segerros is the current CEO of Nicox.
Nicox is a funded company, having raised a total of $271.01M across 12 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Nicox is 5.
Annual revenue of Nicox is $8.17M as on Dec 31, 2024.
Developer of nitric oxide (NO) based therapeutics for glaucoma. The company has developed Nitric Oxide (NO) donating compounds that are used to maintain the intraocular pressure (IOP) in the eyes to prevent glaucoma. The companys lead candidates are VYZULTA (licensed), NCX 470 (phase III), and PDE5 inhibitors (research) to treat glaucoma, NCX 4251 (phase II) to treat blepharitisdry eyes, ZERVIATE (licensed) to treat allergic conjunctivitis, and NCX 4280 to treat morning eye congestion.
Nicox's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Nicox offers NCX 470.
Yes, Nicox is publicly traded on EURONEXT under the ticker symbol ALCOX.
Nicox has made 2 acquisitions, including Aciex Therapeutics, and Carragelose.
Nicox has 7 investors. Key investors include Merck, Pfizer, HBM Healthcare Investments, Eyevance, and Armistice Capital.
The ticker symbol of Nicox is ALCOX on EURONEXT.